CALL/AMGEN/500/0.1/16.01.26 | Market Closed - Bid/Ask 11:55:16 17/05/2024 pm IST | After market 01:29:10 am | |||
| 0.455 EUR | -4.61% |
|
0.464 | +1.98% |
| Current month | +136.14% | ||
| 1 month | +207.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.455 | -4.61% |
| 16/24/16 | 0.477 | +2.80% |
| 15/24/15 | 0.464 | +23.73% |
| 14/24/14 | 0.375 | +3.59% |
| 13/24/13 | 0.362 | -11.71% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 11:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Goldman Sachs |
| WKN | GG24FR |
| ISIN | DE000GG24FR2 |
| Date issued | 23/01/2024 |
| Strike | 500 $ |
| Maturity | 16/01/2026 (609 Days) |
| Parity | 10 : 1 |
| Emission price | 0.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.478 € |
|---|---|
| Lowest since issue | 0.123 € |
| Spread | 0.1 € |
| Spread % | 19.61% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
314.7
USD
Average target price
314.1
USD
Spread / Average Target
-0.21%
- Stock Market
- Warrants
- Warrant
